Source comparison
Melanotan-2 vs Other Appetite-Suppression Protocols: Mechanism Comparison
Melanotan-2 MC4R agonism in hypothalamus. Central appetite circuit modulation 30–60 minutes 4–8 hours Daily, pre-meal Rapid-onset, short-duration intervention. Ideal for targeting specific eating windows rather than 24-hour suppression. Requires precise timing
This comparison does not assign a generated winner or score.
- Melanotan-2
- MC4R agonism in hypothalamus. Central appetite circuit modulation
- 30–60 minutes
- 4–8 hours
- Daily, pre-meal
- Rapid-onset, short-duration intervention. Ideal for targeting specific eating windows rather than 24-hour suppression. Requires precise timing.
- Semaglutide (GLP-1)
- GLP-1 receptor agonism. Slows gastric emptying and prolongs satiety hormone elevation
- 4–8 hours (initial), peak effect at 12+ weeks
- Continuous (weekly injection)
- Weekly
- Sustained appetite suppression through gut-brain axis. Longer onset, broader metabolic effects. Requires 8+ weeks to reach therapeutic effect.
- Tesofensine
- Triple reuptake inhibitor (dopamine, norepinephrine, serotonin). Increases synaptic neurotransmitter availability
- 2–4 hours
- 8–12 hours
- Daily, morning dose
- Central stimulant-like mechanism without amphetamine structure. Stronger than MT-2 for absolute hunger reduction but higher cardiovascular side-effect risk.
- Liraglutide (GLP-1)
- GLP-1 receptor agonism. Gastric delay and satiety hormone modulation
- 6–12 hours
- Continuous (daily injection)
- Daily
- Similar mechanism to semaglutide but shorter half-life requires daily dosing. Lower peak appetite suppression than weekly semaglutide formulations.
- MT-2 occupies a unique niche: it's the only compound in common research use that directly activates hypothalamic appetite circuits without affecting gut motility or systemic metabolism. The trade-off is shorter duration and meal-aligned dosing requirements.